My Companies
Notification
Account
Log Out
Login
gAdvair Diskus FDA approval all strengths, US $172M, One India record ₹3,516Cr +12%, EBITDA 18.7%, gProventil No.1 22%, launches Nintedanib/Dapagliflozin/Liraglutide, ANDAs 281
Cipla Partners With Qilu To License Keytruda Biosimilar In US
Cipla Signs Exclusive License With SBP For TQB2102 HER2 ADC
Cipla Receives VAI Classification For InvaGen New York Inspection
Cipla Receives Seven Form 483 Observations At Pithampur Facility
Cipla Receives US FDA Approval For Generic Advair Diskus Inhaler